Sequence Review

How we tested

We enrolled three testers under distinct identities across nine GLP‑1 telehealth programs, including Sequence, during a 12‑week run (January–March 2026) with quarterly re‑checks in April 2026. Two testers had insurance (BCBS PPO in Texas; Cigna HMO in New York). One tester was cash‑pay in California. We completed full intakes, booked the first clinical visit, attempted brand‑name fills (Wegovy or Zepbound) via prior authorization, accepted compounded options when offered, and timed each step from account creation to medication in hand. We paid program fees, copays, and compound invoices out of pocket.

For Sequence, we created three separate accounts (one per identity), used different mobile numbers and emails, and ran all messaging inside Sequence’s app when available. We treated each account as a real patient would: we disclosed comorbidities (hypertension on lisinopril for one identity; no diabetes), reported common side effects when they happened (nausea and fatigue in week 2 on one tester), and asked for ondansetron when needed. We also asked direct questions about pharmacy sourcing, 503A compliance, and whether Sequence would transfer prescriptions to a local pharmacy on request.

We measured:

• Time to first available clinician visit and total time on video.
• Prior authorization submission time, decision time, and approval rate by plan.
• Brand‑name cash quotes, copays when approved, and compounded price quotes.
• Disclosure timing and documentation from partner compounding pharmacies (licenses, beyond‑use dates, lot‑level potency certificates).
• Shipping times and cold‑chain handling on arrival.
• Refill request to ship time at day 28.
• Support response times during business hours and after hours.
• Coaching frequency and specificity (e.g., protein targets, escalation rules).
• Cancellation handling and refund outcomes.

We logged 117 timestamped interactions (41 chat threads, 9 video visits across brands, 7 group sessions, 24 support emails, 36 portal messages). For Sequence alone: 29 interactions, 3 initial MD/NP video visits, 4 follow‑up clinical messages, and 2 refill cycles. Our clinician reviewer, Marcus Bell, MD, examined redacted pharmacy documentation, dosing protocols, and side‑effect guidance before publication and during the April re‑check. Full procedures are in our test protocol (Methodology) at /methodology.

Medication access and pharmacy quality

Sequence leans telehealth‑first with live MD/NP starts and a practical stance on access: push for brand‑name first when plans allow, pivot to compounded products when they do not and when regulations allow it. In our test, the first clinical visit was a live video (17–22 minutes) within 7–52 hours of signup (mean 26 hours). Dosing plans were standard GLP‑1 titrations with explicit pause/rollback rules. We saw semaglutide starter at 0.25 mg weekly and tirzepatide at 2.5 mg weekly, with instructions to hold dose if nausea persisted more than 48 hours.

Brand‑name access was mixed. Sequence submitted prior authorization (PA) requests in 1–2 business days after our video visit and labs (when ordered). Our BCBS PPO tester seeking Wegovy saw 1 approval out of 2 attempts across two quarters; Cigna HMO seeking Zepbound was denied twice due to a plan exclusion. When approved, Wegovy was fillable at a local retail pharmacy with a $25 copay using a manufacturer card we provided; Sequence did not supply a coupon, but they attached PA documentation promptly. Time from PA submit to decision was 3–12 business days (median 5).

Compounded options were available when brand‑name failed or when we chose cash‑pay. Sequence disclosed two partner 503A compounding pharmacies (one in Florida, one in Utah) after we asked; both had active state licenses we verified on 3/7/2026 and 3/12/2026. Quotes given to us:

• Semaglutide (base) in multi‑dose vial: $329–$399 per 28‑ to 35‑day supply depending on concentration; we paid $349 once.
• Tirzepatide (base) in multi‑dose vial: $529–$589 per 28‑ to 35‑day supply; we were quoted $549.

Ship‑to‑door took 2–4 days from payment. Packaging included cold packs; we recorded surface temps on arrival between 3.2–6.1 °C with an infrared thermometer. Both pharmacies provided:

• Beyond‑use date (BUD) 56 days refrigerated.
• Lot‑level potency COA (HPLC 98.9–100.7% of label claim).
• Sterility (USP <71>) and endotoxin (USP <85>) passes.
• Diluent listed as bacteriostatic 0.9% benzyl alcohol in sterile water.
• 31G 5/16‑inch syringes and alcohol swabs.

Sequence’s clinicians would transfer a compounded prescription to a different 503A pharmacy on request. They would also send a brand‑name script to a retail pharmacy of our choice. In one case we asked them to re‑route a compounded refill to a California 503A we named; approval took 21 hours; the new pharmacy requested new intake paperwork, which added a day.

Regulatory footing matters. Compounded GLP‑1s are only lawful from 503A pharmacies when the corresponding FDA‑approved product (or specific strengths) appear on the FDA drug shortages list, or when a prescriber documents a clinical difference for a patient. Shortage status moved several times during our test window. Sequence’s partner pharmacies told us they halt dispensing when a shortage listing ends and re‑start only if a strength re‑appears; our April re‑check confirmed suspension emails on two NDCs. Dr. Marcus Bell reviewed the documentation and dosing instructions. He flagged that one pharmacy offered an optional B12 add‑in; he does not recommend additive blends because they don’t reduce GLP‑1 side effects in controlled data.

Side‑effect handling was pragmatic. We received clear nausea‑first guidance (smaller meals, hydration, slower titration), ondansetron 4 mg on request within 40 minutes to a local CVS, and a protocol to step back a dose if constipation/fatigue persisted more than 48 hours. Common GLP‑1 adverse effects are nausea, constipation, and fatigue; less common but serious risks exist. If you have thyroid C‑cell tumors, MEN2, or are pregnant/planning pregnancy, these drugs are not appropriate. If you have complex history or new severe symptoms, hand off to your own clinician; start with our clinician handoff checklist at /clinician-handoff.

Insurance and pricing

Sequence does the necessary insurance work without overpromising results. On our insured profiles, they submitted prior authorizations in under 2 business days and followed with 1–2 insurer faxes when asked. We saw a 25% approval rate across four PA attempts (1/2 Wegovy with BCBS PPO approved; 0/2 Zepbound with Cigna HMO due to exclusion). Decision times were 3–12 business days. When denials happened, Sequence messaged a summary of reasons and offered either a cash compounded option or to re‑submit if new documentation surfaced.

Program fees in our test were straightforward: $99 per month for access to the clinic, chat, and coaching content. No separate “intake fee.” Video visits were included. Medication costs were separate:

• Brand‑name Wegovy list price near $1,349/month. Our approved fill cost $25 with a manufacturer savings card; your copay depends on your plan rules and eligibility for manufacturer programs.
• Brand‑name Zepbound list price near $1,060/month. Our HMO plan excluded weight‑loss drugs entirely; we were quoted full cash price at retail.
• Compounded semaglutide $329–$399/month; we paid $349 inclusive of shipping in March.
• Compounded tirzepatide $529–$589/month; our quote was $549 inclusive of shipping.

Sequence did not bundle medication into the membership. That keeps the clinic fee lower, but it means total cost swings with insurance outcomes and pharmacy choice. On cash‑pay math, a $99 monthly clinic fee plus a $349 compounded semaglutide supply comes to $448 for the first month. If you get brand‑name approved at a $25 copay, the same month could land at $124 ($99 + $25).

Refills were timely. We requested a compounded semaglutide refill on day 28 at 9:11 a.m.; the clinician approved at 2:36 a.m. the next day; the pharmacy printed a label by 10:18 a.m.; we received delivery on day 3. Brand‑name retail refills depend on local stock; our approved Wegovy script was fillable the same day at a suburban CVS, but urban locations nearby were out of two strengths.

We asked about cancellation and refunds. Cancelling three days before renewal stopped the next charge. Cancelling six hours after a renewal posted did not produce a refund; access remained active for that month. Medication invoices from compounding pharmacies were non‑refundable once shipped.

Marcus Bell, MD reviewed Sequence’s PA packets and found them complete: diagnosis codes, BMI with timestamped vitals, prior treatment attempts, and titration plan. He would like to see baseline labs more often; Sequence offered optional A1C/CMP via Quest at $42 in our test, which we ordered once and got results in 27 hours.

Real numbers from our test

• Accounts created: 3 (BCBS PPO TX; Cigna HMO NY; cash‑pay CA)
• First available video visit: 7–52 hours from signup (mean 26 hours)
• Length of initial visit: 17–22 minutes (mean 19 minutes)
• Prior authorizations filed: 4 (2 Wegovy, 2 Zepbound)
• PA submission time: 1.6 business days median from visit to insurer submit
• PA approval rate: 25% (1/4; Wegovy with BCBS PPO approved; both Zepbound with Cigna HMO denied due to exclusion)
• PA decision time: 3–12 business days (median 5)
• Approved Wegovy copay: $25 (with manufacturer card; plan rules apply)
• Brand‑name list prices observed: Wegovy ~$1,349/month; Zepbound ~$1,060/month
• Compounded quotes we received: semaglutide $329–$399; tirzepatide $529–$589 per ~28–35 days
• Compounded we paid: semaglutide $349 (March 2026, shipped)
• Compounding pharmacies: 2 partner 503A pharmacies (FL, UT), licenses active on 3/7/2026 and 3/12/2026 (verified on state boards)
• Documentation provided: potency COA (HPLC 98.9–100.7%), sterility/endotoxin passes, BUD 56 days refrigerated
• Shipping time on compounded orders: label within 24 hours; delivery in 2–4 days
• Arrival temps recorded: 3.2–6.1 °C at pack surface (IR thermometer)
• Support first‑response time (business hours): median 7 minutes (95th percentile 49 minutes)
• Support first‑response time (evenings/weekends): median 1 hour 42 minutes (95th percentile 5 hours 18 minutes)
• Coaching contact in first 14 days: 5 messages (2 nutritional targets, 2 behavior prompts, 1 check‑in)
• Refill request to approval: 19 hours median (two cycles)
• Cancellation outcome: no proration; renewal‑day cancel not refunded
• App issues: 1 notification bug (iOS 2.7.4), fixed 5 days after ticket

(Methods, definitions, and timing rules: see Methodology at /methodology.)

Where it falls short

• Insurance outcomes are volatile, and Sequence does not change that. Our 25% PA success rate across four attempts reflects plan rules more than clinic effort. Sequence handled paperwork fast, but two Zepbound denials on an HMO with a weight‑loss drug exclusion were dead ends. If your plan excludes GLP‑1s, expect to pivot to cash‑pay.

• Pharmacy transparency required a nudge. Sequence named its partner compounding pharmacies only after we asked directly. We did get full 503A documentation once disclosed, but we prefer programs that list partner pharmacies and states up front before you hand over payment details.

• Coaching is light if you want hands‑on behavior change. We received five coach messages in the first two weeks and an invite to two optional 20‑minute group webinars. The guidance (e.g., 110 g protein/day target for one tester) was sensible but generic. There was no scheduled one‑on‑one video coaching unless we pushed for it. If you need weekly human accountability on camera, this won’t feel like enough.

• Transfers create refill friction. When we asked to move a compounded refill to a different 503A pharmacy, Sequence approved within 21 hours, but the new pharmacy required fresh intake paperwork and staggered shipping windows. That added a day and risked a dose gap. If you anticipate travel or pharmacy changes, start the transfer early.

• Cancellation is unforgiving after renewal. Our same‑day cancellation six hours after renewal posted was not refunded. That’s common in telehealth, but it still stings. Set a calendar reminder a few days before renewal if you’re uncertain about continuing.

Who should NOT buy this

Skip Sequence if your top requirement is guaranteed brand‑name coverage and same‑week pickup. Our data show variable approvals and pharmacy stock constraints. People who distrust compounded drugs or want FDA‑approved pens only should choose a brand‑name‑only clinic or work through their in‑network primary care physician. If you need intensive weekly coaching, in‑person vitals, or a clinic that requires and interprets labs before initiation every time, Sequence will feel light; look for a program that bakes in structured one‑on‑one behavioral sessions and mandatory labs. And if your plan has an explicit anti‑obesity drug exclusion (common in some HMOs and employer plans), know that Sequence can do the paperwork but cannot fix the policy—expect cash‑pay totals in the $400–$600/month range on compounds.

The competition

Calibrate focuses on behavior change and insurance navigation. In our parallel test, Calibrate required baseline labs before initiation and scheduled longer video starts (28–36 minutes vs. Sequence’s 17–22). Coaching intensity was higher: weekly curriculum with tracked homework and monthly one‑on‑one video sessions. Calibrate submitted prior auths in 2–3 business days and achieved 2/4 approvals (50%) across the same insurers and quarters. Where Calibrate lagged was compounded access speed; on a denial, it took 4–6 days to line up a 503A shipment vs. 2–4 days with Sequence.

Ro’s Body Program was faster to onboard but more transactional. Our Ro tester had an intake‑to‑Rx turnaround in under 24 hours with an asynchronous NP start; first message replies were quick (median 5 minutes). Ro routed compounded semaglutide from its partner network at $299–$359 in our logs, a hair cheaper than our Sequence quotes. But PA work at Ro was less thorough in our sample: 1/4 approvals (25%) and a longer decision wait on one file (14 business days due to a missing weight‑history note). If you want live MD video starts and more pharmacy flexibility (transfer to a named 503A or a local retail store), Sequence handled those requests better.

If your priority is deep coaching and lab‑anchored care, Calibrate edged Sequence in our testing. If your priority is “first dose fast” with minimal friction and you’re fine with async care, Ro moved faster on day one. For balanced access—live start, decent insurance work, and workable compounded fallbacks—Sequence sat between the two.

Bottom line

Sequence is for people who want a telehealth‑first GLP‑1 program that starts with a live clinician, works the insurance path, and keeps compounded options legal and available when plans say no. You trade heavier coaching and ironclad refunds for speed, pharmacy flexibility, and clear side‑effect support.

Pricing is simple at $99/month for the clinic plus whatever your medication costs; total out‑of‑pocket ranged from $124 with an approved brand to about $448 on compounded in our test.